Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 17, 2023 10:27am

140 Views

Post# 35501671

RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

Swiss Big Pharma Roche has its sights set firmly on early-stage biotechs as potential targets, judging by CEO Thomas Schinecker’s, Ph.D., comments.

“We are always open to M&A, and we always check all the opportunities that are on the market,” Schinecker said on an earnings call April 26. When it comes to companies in early-stage development, “there may be more opportunities now, simply because of the funding issues in the biotech sector.”

“I think in the late-stage opportunities, there are not that many and it's much more competitive,” he continued.

[ONCY is a Phase 3 ready late-stage oncology drug platform company involving pelareorep in the treatment of multiple cancers]